0001733257-18-000001.txt : 20180305 0001733257-18-000001.hdr.sgml : 20180305 20180305144804 ACCESSION NUMBER: 0001733257-18-000001 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06c FILED AS OF DATE: 20180305 DATE AS OF CHANGE: 20180305 EFFECTIVENESS DATE: 20180305 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Finch Therapeutics Group, Inc. CENTRAL INDEX KEY: 0001733257 IRS NUMBER: 823433558 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-306939 FILM NUMBER: 18665599 BUSINESS ADDRESS: STREET 1: 200 INNER BELT ROAD CITY: SOMERVILLE STATE: MA ZIP: 02143 BUSINESS PHONE: 617-229-6499 MAIL ADDRESS: STREET 1: 200 INNER BELT ROAD CITY: SOMERVILLE STATE: MA ZIP: 02143 D 1 primary_doc.xml X0708 D LIVE 0001733257 Finch Therapeutics Group, Inc. 200 INNER BELT ROAD SOMERVILLE MA MASSACHUSETTS 02143 617-229-6499 DELAWARE None None Corporation true 2017 Mark Smith 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Executive Officer Director Andrew Noh 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Director Benjamin Enerson 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Executive Officer Zain Kassam 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Executive Officer James Burgess 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Director Andrew Mulderry 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Director Chris Lange 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Director R. J. Price 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somerville MA MASSACHUSETTS 02143 Director Jeffery A. Smisek 200 Inner Belt Road c/o Finch Therapeutics Group, Inc. Somervlle MA MASSACHUSETTS 02143 Director Biotechnology Decline to Disclose 06c false 2018-02-20 false true true Preferred Stock and Common Stock underlying thereto false 0 36399996 36399996 0 false 14 0 0 0 Proceeds to be used for general working capital purposes. false Finch Therapeutics Group, Inc. /s/ Benjamin Enerson Benjamin Enerson General Counsel and VP of Legal 2018-03-05